Equillium reports positive Phase 2 ulcerative colitis study data
Equillium, Inc. (NASDAQ:EQ), a biotechnology company with a market capitalization of $25.15 million and current stock price of $0.71, announced today the positive outcomes of their Phase 2 clinical ...
AZoRobotics on MSN44 分钟
AI Prediction System for Idiopathic Multicentric Castleman's Disease
Researchers have used AI to find adalimumab effective for iMCD, highlighting the potential of machine learning in discovering ...